FOLH1 and neoplasm: PSMA targeting has rapidly evolved with the development of accurate tumour-targeted imaging with Gallium-68-PSMA imaging and therapy based on the findings on positron emission tomography/computed tomography (68Ga-PSMA-11 PET/CT) and RLT using a number of alternative PSMA ligands labelled with lutetium-177 (177Lu-PSMA RLT).